Tandem Sure Has Been Busy Lately. What’s Up with That?

MD+DI Managing Editor Omar Ford digs into the recent activity and explains what it means for Tandem and what it could mean for companies during the COVID-19 pandemic.

Omar Ford

July 10, 2020

In the last few months, Tandem Diabetes Management has made an acquisition and signed deals with two of medtech's biggest powerhouses - Abbott Laboratories and Medtronic. But what does it all mean? MD+DI's Managing Editor Omar Ford tries to make sense of the companies recent momentum. 

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like